13th Annual ARVD Family Seminar
A seminar and workshops on the latest research advances and treatments for a heart condition known as ARVD—one of the leading causes of sudden death among teenagers, young adults and young athletes. More than 200 patients and their family members from 25 states across the U.S. and Canada will attend.
Saturday, April 28, 2012
8:30 a.m. to 5 p.m.
The Johns Hopkins Hospital
Preclinical Teaching Building
Baltimore, Maryland 21205
ARVD stands for arrhythmogenic right ventricular dysplasia/cardiomyopathy, a life-threatening genetic condition that affects apparently healthy teens and young adults. It is a form of heart disease in which the muscle of the right ventricle is replaced by fat or fibrous tissue, setting the stage for abnormal heart rhythms that can lead to sudden cardiac death or heart failure. Although ARVD often runs in families, it also occurs in people with no family history.
Symptoms include irregular heartbeats, leading to palpitations, fainting or dizziness. ARVD can also cause shortness of breath and swelling in the legs and feet. Diagnosis and proper treatment are crucial to prevent dangerous heart rhythm abnormalities and sudden death.
Treatments include medication, radiofrequency ablation to interrupt the abnormal heart rhythms, and implantable defibrillators for those at highest risk of sudden death. Patients are also advised to restrict their exercise regimens.
The Johns Hopkins ARVD Program was established more than 10 years ago to further the research and care for patients with this rare disease. The program is one of the largest and most comprehensive for ARVD in the world, with a dedicated team of experts including cardiologists and genetic counselors. The team is headed by Hugh Calkins, M.D., the Nicholas J. Fortuin Professor in Cardiology. He is a professor of medicine and director of the Johns Hopkins Cardiac Arrhythmia Service and Electrophysiology Laboratory.
Ellen Beth Levitt, email@example.com,
410-955-5307 (office) or 410-598-4711 (cell).